Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H17ClN2O |
Molecular Weight | 324.804 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC=C2N(CC3CC3)C(=O)CN=C(C4=CC=CC=C4)C2=C1
InChI
InChIKey=MWQCHHACWWAQLJ-UHFFFAOYSA-N
InChI=1S/C19H17ClN2O/c20-15-8-9-17-16(10-15)19(14-4-2-1-3-5-14)21-11-18(23)22(17)12-13-6-7-13/h1-5,8-10,13H,6-7,11-12H2
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/1959497Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/6106488
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1959497
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/6106488
Prazepam is a benzodiazepine derivative and is indicated to treat symptoms of anxiety. Benzodiazepines are used to treat severe incapacitating symptoms or symptoms leading to an extreme suffering for the patient. Prazepam is believed to stimulate GABA receptors in the ascending reticular activating system. Since GABA is inhibitory, receptor stimulation increases inhibition and blocks both cortical and limbic arousal following stimulation of the brain stem reticular formation. Prazepam is a prodrug for N-desmethyl-diazepam, which is responsible for the therapeutic effects of prazepam. Prazepam was discontinued in USA.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=6114911 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PRAZEPAM Approved UseUnknown Launch Date1987 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/387419/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
36 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/387419/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.31 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/387419/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
20 mg 4 times / day multiple, oral Highest studied dose Dose: 20 mg, 4 times / day Route: oral Route: multiple Dose: 20 mg, 4 times / day Sources: |
unhealthy, 44 years (range: 29 - 65 years) Health Status: unhealthy Age Group: 44 years (range: 29 - 65 years) Sex: M Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Electrospray ionization gas-phase electrophoresis under ambient conditions and it's potential or high-speed separations. | 2001 Feb |
|
[Interaction between melilot and acenocoumarol? (Melilotruscus aculeatus)]. | 2001 May-Jun |
|
Anti-spasticity agents for multiple sclerosis. | 2003 |
|
Determination of midazolam and 1'-hydroxymidazolam by liquid chromatography-mass spectrometry in plasma of patients undergoing methadone maintenance treatment. | 2003 Jan 5 |
|
Interface flow process audit: using the patient's career as a tracer of quality of care and of system organisation. | 2004 |
|
Distribution of diazepam and nordiazepam between plasma and whole blood and the influence of hematocrit. | 2004 Aug |
|
[Prescription and use of benzodiazepins in Saint-Louis in Senegal: patient survey]. | 2004 Mar |
|
Development and validation of a liquid chromatographic/electrospray ionization mass spectrometric method for the quantitation of prazepam and its main metabolites in human plasma. | 2005 Apr |
|
Naltrexone plus benzodiazepine aids abstinence in opioid-dependent patients. | 2005 Oct 7 |
|
Induction of a mixed depressive episode during rTMS treatment in a patient with refractory major depression. | 2006 |
|
Quantification of tipranavir in human plasma by high-performance liquid chromatography with UV detection. | 2006 Jan 2 |
|
Benzodiazepines prescription in Dakar: a study about prescribing habits and knowledge in general practitioners, neurologists and psychiatrists. | 2006 Jun |
|
The detection of sedatives in hair and nail samples using tandem LC-MS-MS. | 2007 Feb 14 |
|
[Prescription of benzodiazepines by general practitioners in the private sector of Dakar: survey on knowledge and attitudes]. | 2007 Mar-Apr |
|
Community-based randomised controlled trial evaluating falls and osteoporosis risk management strategies. | 2008 Nov 4 |
|
Contribution of neuroinflammation in burning mouth syndrome: indications from benzodiazepine use. | 2008 Oct |
|
Simultaneous determination of benzodiazepines and their metabolites in human serum by liquid chromatography-tandem mass spectrometry using a high-resolution octadecyl silica column compatible with aqueous compounds. | 2009 Apr |
|
Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine. | 2009 Apr 28 |
|
Fatal intoxications by acenocoumarol, phenprocoumon and warfarin: method validation in blood using the total error approach. | 2009 Aug 1 |
|
Noradrenergic regulation of GABAergic inhibition of main olfactory bulb mitral cells varies as a function of concentration and receptor subtype. | 2009 May |
|
[Neonatal Volkmann's syndrome]. | 2009 Nov |
|
Drugs associated with more suicidal ideations are also associated with more suicide attempts. | 2009 Oct 2 |
|
General unknown screening procedure for the characterization of human drug metabolites in forensic toxicology: applications and constraints. | 2009 Sep |
|
Development and validation of an EI-GC-MS method for the determination of benzodiazepine drugs and their metabolites in blood: applications in clinical and forensic toxicology. | 2010 Aug 1 |
|
Depression, extrapyramidal symptoms, dementia and an unexpected outcome: a case report. | 2010 Feb 2 |
|
The impact of perfectionism and anxiety traits on action monitoring in major depressive disorder. | 2010 Jul |
|
Eight self-administered 24-hour dietary recalls using the Internet are feasible in African Americans and Whites: the energetics study. | 2010 Jun |
|
Evaluation of pregabalin as an adjuvant to patient-controlled epidural analgesia during late termination of pregnancy. | 2010 Nov |
Patents
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N05BA11
Created by
admin on Mon Mar 31 21:26:25 GMT 2025 , Edited by admin on Mon Mar 31 21:26:25 GMT 2025
|
||
|
NCI_THESAURUS |
C1012
Created by
admin on Mon Mar 31 21:26:25 GMT 2025 , Edited by admin on Mon Mar 31 21:26:25 GMT 2025
|
||
|
WHO-VATC |
QN05BA11
Created by
admin on Mon Mar 31 21:26:25 GMT 2025 , Edited by admin on Mon Mar 31 21:26:25 GMT 2025
|
||
|
DEA NO. |
2764
Created by
admin on Mon Mar 31 21:26:25 GMT 2025 , Edited by admin on Mon Mar 31 21:26:25 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID4021181
Created by
admin on Mon Mar 31 21:26:25 GMT 2025 , Edited by admin on Mon Mar 31 21:26:25 GMT 2025
|
PRIMARY | |||
|
1727
Created by
admin on Mon Mar 31 21:26:25 GMT 2025 , Edited by admin on Mon Mar 31 21:26:25 GMT 2025
|
PRIMARY | |||
|
8627
Created by
admin on Mon Mar 31 21:26:25 GMT 2025 , Edited by admin on Mon Mar 31 21:26:25 GMT 2025
|
PRIMARY | RxNorm | ||
|
D011222
Created by
admin on Mon Mar 31 21:26:25 GMT 2025 , Edited by admin on Mon Mar 31 21:26:25 GMT 2025
|
PRIMARY | |||
|
4890
Created by
admin on Mon Mar 31 21:26:25 GMT 2025 , Edited by admin on Mon Mar 31 21:26:25 GMT 2025
|
PRIMARY | |||
|
CHEMBL969
Created by
admin on Mon Mar 31 21:26:25 GMT 2025 , Edited by admin on Mon Mar 31 21:26:25 GMT 2025
|
PRIMARY | |||
|
220-975-8
Created by
admin on Mon Mar 31 21:26:25 GMT 2025 , Edited by admin on Mon Mar 31 21:26:25 GMT 2025
|
PRIMARY | |||
|
PRAZEPAM
Created by
admin on Mon Mar 31 21:26:25 GMT 2025 , Edited by admin on Mon Mar 31 21:26:25 GMT 2025
|
PRIMARY | |||
|
2240
Created by
admin on Mon Mar 31 21:26:25 GMT 2025 , Edited by admin on Mon Mar 31 21:26:25 GMT 2025
|
PRIMARY | |||
|
m9106
Created by
admin on Mon Mar 31 21:26:25 GMT 2025 , Edited by admin on Mon Mar 31 21:26:25 GMT 2025
|
PRIMARY | Merck Index | ||
|
DB01588
Created by
admin on Mon Mar 31 21:26:25 GMT 2025 , Edited by admin on Mon Mar 31 21:26:25 GMT 2025
|
PRIMARY | |||
|
Q30VCC064M
Created by
admin on Mon Mar 31 21:26:25 GMT 2025 , Edited by admin on Mon Mar 31 21:26:25 GMT 2025
|
PRIMARY | |||
|
2955-38-6
Created by
admin on Mon Mar 31 21:26:25 GMT 2025 , Edited by admin on Mon Mar 31 21:26:25 GMT 2025
|
PRIMARY | |||
|
SUB10006MIG
Created by
admin on Mon Mar 31 21:26:25 GMT 2025 , Edited by admin on Mon Mar 31 21:26:25 GMT 2025
|
PRIMARY | |||
|
100000092249
Created by
admin on Mon Mar 31 21:26:25 GMT 2025 , Edited by admin on Mon Mar 31 21:26:25 GMT 2025
|
PRIMARY | |||
|
1554501
Created by
admin on Mon Mar 31 21:26:25 GMT 2025 , Edited by admin on Mon Mar 31 21:26:25 GMT 2025
|
PRIMARY | |||
|
277179
Created by
admin on Mon Mar 31 21:26:25 GMT 2025 , Edited by admin on Mon Mar 31 21:26:25 GMT 2025
|
PRIMARY | |||
|
7275
Created by
admin on Mon Mar 31 21:26:25 GMT 2025 , Edited by admin on Mon Mar 31 21:26:25 GMT 2025
|
PRIMARY | |||
|
C66458
Created by
admin on Mon Mar 31 21:26:25 GMT 2025 , Edited by admin on Mon Mar 31 21:26:25 GMT 2025
|
PRIMARY |
ACTIVE MOIETY